Dr. Kuske on APBI Via Multicatheter Interstitial Brachytherapy

Robert R. Kuske, MD
Published: Thursday, Nov 26, 2015



Robert R. Kuske, MD, radiation oncologist, Arizona Breast Cancer Specialists, discusses an analysis of the Pooled Registry of Multicatheter Interstitial Sites (PROMIS) Experience, which examined the safety of accelerated partial breast irradiation (APBI) via multicatheter interstitial brachytherapy.

Previous studies show that APBI is non-inferior to whole breast irradiation, Kuske adds. The PROMIS analysis examined more than 1300 patients treated with APBI at five institutions. Patients had > 2 cm beyond the lumpectomy cavity in all dimensions.

With APBI, the treatment time was shortened from 6 weeks to 5 days, Kuske explains, and reduced radiation exposure to the lung and heart. Data showed that cosmetic outcomes were reported as 'good' or 'excellent' in 91% of patients. Also, rates of infection, fibrosis, and telangiectasia were found to be significantly low.

SELECTED
LANGUAGE


Robert R. Kuske, MD, radiation oncologist, Arizona Breast Cancer Specialists, discusses an analysis of the Pooled Registry of Multicatheter Interstitial Sites (PROMIS) Experience, which examined the safety of accelerated partial breast irradiation (APBI) via multicatheter interstitial brachytherapy.

Previous studies show that APBI is non-inferior to whole breast irradiation, Kuske adds. The PROMIS analysis examined more than 1300 patients treated with APBI at five institutions. Patients had > 2 cm beyond the lumpectomy cavity in all dimensions.

With APBI, the treatment time was shortened from 6 weeks to 5 days, Kuske explains, and reduced radiation exposure to the lung and heart. Data showed that cosmetic outcomes were reported as 'good' or 'excellent' in 91% of patients. Also, rates of infection, fibrosis, and telangiectasia were found to be significantly low.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Publication Bottom Border
Border Publication
x